Literature DB >> 7112514

Distinction of two pathologic antithrombin III molecules: antithrombin III "Aalborg' and antithrombin III "Budapest'.

P J Sørensen, G Sas, I Petó, G Blaskó, T Kremmer, A Samu.   

Abstract

Plasma from two different thrombophilic families with functional inherited antithrombin III deficiency, i.e., with low antithrombin III activity but normal immunoreactive antithrombin III concentration, were investigated simultaneously in the same laboratory. The experiments (thrombin and Factor Xa inactivation, heparin affinity chromatography, modified two dimensional immunoelectrophoresis and gel filtration) showed a distinct difference between the two antithrombin III anomalies. The antithrombin III "Aalborg' had decreased thrombininactivating activity but normal Factor Xa-inactivating activity. The heparin affinity and the molecule weight are normal. The antithrombin III "Budapest' displays a more profound abnormality with pathologic thrombin and Factor Xa inactivation, decreased heparin affinity and abnormal molecular weight.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7112514     DOI: 10.1016/0049-3848(82)90142-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Evidence linking familial thrombosis with a defective antithrombin III gene in two British kindreds.

Authors:  S H Sacks; J M Old; S T Reeders; D J Weatherall; A S Douglas; J H Winter; C R Rizza
Journal:  J Med Genet       Date:  1988-01       Impact factor: 6.318

2.  Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Authors:  J E Sambrano; L J Jacobson; E B Reeve; M J Manco-Johnson; W E Hathaway
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

3.  Relation between antithrombin III and clinical and serological parameters in systemic lupus erythematosus.

Authors:  M P Jarrett; D Green; C H Ts'ao
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.